Opinions Jim Cramer - Mad Money
TG TherapeuticsTGTXBUYOct 20, 2020
A biopharma. Dont sell. Great CEO. It took a long time, but the stock is now paying off.
Jim Cramer - Mad MoneyUnknown
$28.66
Stock price when the opinion was issued
$61.04
As of Nov 03, 2026. Market Open.
biotechnology
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly
The developer of a medication for relapsing MS in patients has seen an 88% reduction in progression after seven years of usage. It trades at 13x earnings and supports a 100% ROE. We like that quarterly cash reserves are growing along with cash flow. We recommend setting a stop-loss at $41, looking to achieve $70 -- upside potential of 30%. Yield 0%
(Analysts’ price target is $69.70)
biotechnology
BUY
Developing drugs for MS and blood cancers like leukemia. Exciting prospects; boasts promising clinical trial results, especially for their MS drug. Last month, they announced good phase 3 results for that drug which lifted share from the $30's to $50's. Cash flow is fine; they just said they've raised a lot of money.
biotechnology
